Optical Coherence Tomography May Improve Safety and Outcomes for Stenting Procedures in Heart Disease Patients Compared to Conventional Angiography

Results from a large-scale clinical trial results could increase usage of high resolution imaging for guiding interventional coronary procedures

University Hospitals Research Published in New England Journal of Medicine Shows Minimally Invasive Procedure Saves Most Patients with Severe Vascular Disease from Amputation

A study, co-led by University Hospitals Harrington Heart & Vascular Institute, could lead to the first FDA approval of a therapy giving thousands of patients hope for an alternative to amputation.

Medicamento brentuximab vedotina pode melhorar a sobrevida geral de pacientes com linfoma de Hodgkin

Um estudo conduzido por pesquisadores do Centro de Câncer da Mayo Clinic descobriu que adicionar o brentuximab vedotina ao tratamento quimioterápico padrão aumenta a taxa geral de sobrevida de pacientes com linfoma de Hodgkin, em comparação com o padrão de tratamento atual que usa somente a quimioterapia.

New research uncovers how cancers with common gene mutation develop resistance to targeted drugs

A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time. The findings, reported online today in the New England Journal of Medicine, underscore the need for new drugs that inhibit KRAS differently than current agents do.

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.

CD19 CAR NK-cell therapy achieves 73% response rate in patients with leukemia and lymphoma

According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.